Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 μg/salmeterol 50 μg compared with ipratropium for chronic obstructive pulmonary disease in older adults

American Journal Geriatric Pharmacotherapy

Volumn 6, Issue 3, 2008, Pages 138-146

  Blanchette, Christopher M ^a   Akazawa, Manabu ^b   Dalal, Anand ^c   Simoni Wastila, Linda ^d  

^a LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^b IL   (United States)

^c GLAXOSMITHKLINE   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

chronic obstructive pulmonary disease; COPD; exacerbation; initial maintenance therapy; Medicare; treatment cost

Indexed keywords

ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID DERIVATIVE; FLUTICASONE PROPIONATE PLUS SALMETEROL; IPRATROPIUM BROMIDE; THEOPHYLLINE;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; COST OF ILLNESS; DISEASE EXACERBATION; DRUG COST; DRUG EFFICACY; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION COST; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICARE; OBSERVATIONAL STUDY; PATIENT IDENTIFICATION; PRESCRIPTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; SENSITIVITY ANALYSIS;

AGED; ALBUTEROL; ANDROSTADIENES; BRONCHODILATOR AGENTS; COHORT STUDIES; COSTS AND COST ANALYSIS; DATABASES, FACTUAL; DRUG COMBINATIONS; EMERGENCY SERVICE, HOSPITAL; FEMALE; HOSPITALIZATION; HUMANS; IPRATROPIUM; MALE; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; RISK; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 50449087598     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2008.08.005     Document Type: Article

References (34)

1. Global strategy for the diagnosis, management and prevention of COPD. http://www.goldcopd.org/Guidelineitem.asp?ll=2&12=l&intId=989. Accessed April 22, 2008.
2. Mannino D.M., Homa D.M., Akinbami L.J., et al. Chronic obstructive pulmonary disease surveillance-United States, 1971-2000. MMWR Surveill Suture 51 (2002) 1-16
3. Halpern M.T., Stanford R.H., and Borker R. The burden of COPD in the USA: Results from the Confront- ing COPD survey. Respir Med 97 Suppl C (2003) S81-S89
4. Cydulka R.K., McFadden Jr. E.R., Emerman C.L., et al. Patterns of hospitalization in elderly patients with asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 156 (1997) 1807-1812
5. Miravitlles M., Murio C., Guerrero T., Gisbert R., and DAFNE Study Group (Decisiones sobre Antibioticoterapia y Farmacoeconomia en la EPOC). Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 121 (2002) 1449-1455
6. Cormors Jr. A.F., Dawson N.V., Thomas C., et al., SUPPORT Investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Outcomes following acute exacerbations of severe chronic obstructive lung disease [published correction appears in Am J Respir Crit Care Med. 1997;155:386]. Am J Respir Crit Care Med 154 (1996) 959-967
7. Seemungal T.A., Donaldson G.C., Paul E.A., et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157 (1998) 1418-1422
8. Miravitlles M., Ferrer M., Pont A., et al., IMPAC Study Group. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: A 2 year follow up study. Thorax 59 (2004) 387-395
9. Mapel D.W., Hurley J.S., Frost F.J., et al. Health care utilization in chronic obstructive pulmonary disease. A case-control study in a health maintenance organization. Arch Intern Med 160 (2000) 2653-2658
10. Strassels S.A., Smith D.H., Sullivan S.D., and Mahajan P.S. The costs of treating COPD in the United States. Chest 119 (2001) 344-352
11. Burge P.S., Calverley P.M., Jones P.W., et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial. BMJ 320 (2000) 1297-1303
12. Paggiaro P.L., Dahle R., Bakran I., et al., International COPD Study Group. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease [published correction appears in Lancet. 1998;351:1968]. Lancet 351 (1998) 773-780
13. Szafranski W., Cukier A., Ramirez A., et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease [published correction appears in Eur Respir J. 2003;21:912]. Eur Respir J 21 (2003) 74-81
14. Jones P.W., Willits L.R., Burge P.S., Calverley P.M., and Inhaled Steroids in Obstructive Lung Disease in Europe Study Investigators. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 21 (2003) 68-73
15. Sin D.D., McAlister F.A., Man S.F., and Anthonisen N.R. Contemporary management of chronic obstructive pulmonary disease: Scientific review. JAMA 290 (2003) 2301-2312
16. Standards for the diagnosis and management of patients with COPD. http://www.thoracic.org/sections/copd. Accessed April 22, 2008.
17. Wu E.Q., Patel P.A., Yu A.P., et al. Disease-related and all-cause health care costs of elderly patients with gout. J Manag Care Pharm 14 (2008) 164-175
18. Mapel D.W., Frost F.J., Hurley J.S., et al. An algorithm for the identification of undiagnosed COPD cases using administrative claims data. J Manag Care Pharm 12 (2006) 457-465
19. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 15 (2006) 291-303
20. Baser O. Too much ado about propensity score models? Comparing methods of propensity score matching. Value Health 9 (2006) 377-385
21. Akazawa M., Hayflinger C.D., Stanford R.H., and Blanchetre C.M. Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease. Am J Manag Care 14 (2008) 438-448
22. Rascati K.L., Stanford R.H., and Borker R. A comparison of the risk of hospitalizations due to chronic obstructive pulmonary disease in Medicaid patients with various medication regimens, including ipratropium, inhaled corticosteroids, salmeterol, or their combination. Clin Ther 27 (2005) 346-354
23. Rascati K.L., Akazawa M., Johnsrud M., et al. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen. Clin Ther 29 (2007) 1203-1213
24. Calverley P.M., Anderson J.A., Celli B., et al., TORCH Investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 (2007) 775-789
25. 2 Agonists Study Group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomised controlled trial [published correction appears in Lancet. 2003;361:1660]. Lancet 361 (2003) 449-456
26. Vestbo J., Pauwels R., Anderson J.A., et al., TRISTAN Study Group. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax 60 (2005) 301-304
27. Adams S.G., Melo J., Luther M., and Anzueto A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 117 (2000) 1345-1352
28. Macfarlane J.T., Colville A., Guion A., et al. Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community. Lancet 341 (1993) 511-514
29. Ball P., Harris J.M., Lowson D., et al. Acute infective exacerbations of chronic bronchitis. QJM 88 (1995) 61-68
30. Dewan N.A., Rafique S., Kanwar B., et al. Acute exacerbations of COPD: Factors associated with poor treatment outcome. Chest 117 (2000) 662-671
31. Donohue J.F., Kalberg C., Emmett A., et al. A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD. Treat Respir Med 3 (2004) 173-181
32. Make B., Hanania N.A., ZuWallack R., et al. The efficacy and safety of inhaled fluticasone propionate/ salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: An eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. Clin Ther 27 (2005) 531-542
33. Advair Diskus ® product labeling, http://www.fda.gov/cder/foi/label/2006/O21077sO281bl.pdf. Accessed July 21, 2008.
34. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf 16 (2007) 241-249